The FDA has approved SimpleScreen CRC, a blood-based screening test developed by Freenome, for average-risk adults aged 45 and older. The test detects cell-free DNA linked to colorectal cancer, and Abbott plans to make it commercially available this fall. The approval is based on results from the PREEMPT CRC study. The test detected 81.1% of […]
FDA Approves Blood Test for Colorectal Cancer Screening Read More »
The phase 2 CHIMERA trial is evaluating whether adding pembrolizumab to standard chemotherapy before and after surgery can improve outcomes for patients with resectable pleural mesothelioma. About 40 adults with previously untreated stage I to IIIa epithelioid or biphasic disease are expected to enroll. Patients will receive three cycles of pembrolizumab combined with platinum-based chemotherapy
CHIMERA Trial Tests Pembrolizumab Around Surgery for Pleural Mesothelioma Read More »
Updated results from the phase 1a FIT-001 trial show that darlifarnib (KO-2806) combined with cabozantinib produced encouraging results in patients with advanced clear cell renal cell carcinoma (ccRCC) who had not previously received cabozantinib. The overall response rate ranged from 33% to 50% across the dose groups, and the median progression-free survival was 13 months.
Darlifarnib Plus Cabozantinib Shows Promising Activity in Advanced Kidney Cancer Read More »
A phase 3 study of cretostimogene grenadenorepvec showed encouraging results in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). The treatment produced a complete response in 75.5% of patients at some point during the study. The responses were long-lasting, with a median duration of at least 27.9 months. More
Phase 3 Trial Shows Durable Responses With Cretostimogene in High-Risk Bladder Cancer Read More »
Updated results from the phase 2 J201 study show that safusidenib continues to demonstrate promising long-term activity in patients with treatment-naive grade 2 IDH1-mutant glioma. After a median follow-up of 38.8 months, the drug achieved a confirmed overall response rate of 51.9%, while 79.1% of patients remained free from disease progression at 36 months. The
Safusidenib Shows Durable Activity in IDH1-Mutant Glioma, New Trials Begin Read More »
Daraxonrasib (RMC-6236) has been accepted by the FDA for review as a treatment for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The oral drug targets multiple RAS mutations, which are found in more than 90% of PDAC tumors. The application is being reviewed through the FDA Commissioner’s National Priority Voucher pilot program, which could shorten
FDA Accepts Daraxonrasib Application for Pancreatic Cancer Read More »
Results from the phase 1a/b TRAVERSE trial suggest that ALLO-316, an off-the-shelf CAR T-cell therapy targeting CD70, may be a promising treatment for patients with advanced clear cell renal cell carcinoma (ccRCC). The study included 51 heavily pretreated patients whose cancer had progressed after checkpoint inhibitors and VEGFR-targeted therapies. In the phase 1b group, ALLO-316
Off-the-Shelf CAR T-Cell Therapy Shows Promise in Advanced Kidney Cancer Read More »
The final 10-year results from the phase 3 RELEVANCE trial show that the chemotherapy-free combination of lenalidomide plus rituximab (R²) provides long-term outcomes similar to standard immunochemotherapy for patients with previously untreated advanced follicular lymphoma. The study included 1,030 adults and followed them for a median of nearly 10 years. Patients treated with R² had
10-Year Study Confirms Chemo-Free Option for Follicular Lymphoma Read More »
Results from the phase 2 KEYPAD trial suggest that combining pembrolizumab with denosumab may benefit patients with advanced clear-cell renal cell carcinoma (ccRCC) whose cancer progressed after previous VEGFR-targeted therapy. The Australian single-arm study enrolled 59 patients with unresectable or metastatic disease. The combination achieved an objective response rate of 31%, with all responses being
Pembrolizumab Plus Denosumab Shows Promising Activity in Pretreated Kidney Cancer Read More »
Early results from the phase 1 META 10-19 trial presented at the 2026 ASCO Annual Meeting showed encouraging outcomes for patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Among 14 evaluable patients treated with ultra-low doses of the IL-10–expressing anti-CD19 CAR T-cell therapy, the objective response rate was 100%, and 92.9% achieved
META 10-19 CAR T Therapy Delivers Durable Responses in High-Risk DLBCL Read More »